Guizhou Bailing Group Pharmaceutical Co Ltd002424
▼ NegativeCapitalrelevance
Net profit down 42.07% and revenue down 33.62% in interim report.
Impact on stocks 1
Others
Guizhou Bailing Group Pharmaceutical Co LtdST Bailing released its 2026 interim report, with net profit attributable to the parent company at 30.03 million yuan, down 42.07% from the same period last year. Total operating revenue was 970 million yuan, down 33.62% year-on-year. Net cash inflow from operating activities was 72.64 million yuan, down 70.87% year-on-year. The latest asset-liability ratio was 43.95%, gross margin was 41.78%, ROE was 0.94%, and diluted earnings per share was 0.02 yuan.
Guizhou Bailing Group Pharmaceutical Co LtdNet profit down 42.07% and revenue down 33.62% in interim report.